Targeted therapy for lung adenocarcinoma is to take advantage of the differences in molecular biology between tumor cells and normal cells, using methods such as blocking signaling pathways, closing receptors, and inhibiting angiogenesis to act on specific targets of tumor cells, specifically inhibiting tumor cell proliferation, invasion and metastasis, and promoting their apoptosis. Due to the specificity of the target, molecular targeted therapy has higher selectivity and less toxic side effects than traditional therapy, and targeted therapy has been clinically applied for more than 20 years.